Operator Good morning, and welcome to Ocugen's fourth quarter and full-year 2024 financial results and business update.

Q4 2024 Earnings Call Transcript March 5, 2025 Ocugen, Inc. reports earnings inline with expectations. Reported EPS is $-0.05 ...

Ocugen Inc (OCGN) outlines pivotal trial progress and financial strategies while navigating increased expenses and market ...

OCU200 moved into the clinic, and patients are currently being dosed in Phase 1 clinical trial for diabetic macular edema, DME. OCU200 has the potential to change the treatment landscape for DME ...

Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen’s leadership team will host the call, which will be ...

Ocugen’s biologic candidate moved into the clinic and patients are currently being dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). OCU200 has the potential to change ...